Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In Taiwan
NCT02924584
Last updated date
ABOUT THIS STUDY
Breast cancer is the most common cancer in Taiwanese women. Most of them were diagnosed in
relatively early stages. Only 700 metastatic breast cancer were registered in Official Cancer
Registration 2012, while more than11,305 were registered as early breast cancer. With broadly
application of aromatase inhibitors, hormonal-receptor-positive breast cancer patients can
survive longer and longer. However, there is no prevalence of metastatic breast cancer can be
available yet. NHIA database coverage is more than 90% population in Taiwan, thus it can be
an appropriate surrogate of prevalence. In this retrospective database analysis, we will
explore the real world experience on aromatase inhibitor use for breast cancer in Taiwan.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Her2(-) Breast Cancer ER/PR(+)
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
0 +
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- hormonal receptor positive, human epidermal growth factor receptor 2 negative breast cancer
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
-
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Her2(-) Breast Cancer ER/PR(+)Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In Taiwan
NCT02924584
- Tainan City,
ALL GENDERS
0+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | |||||
|---|---|---|---|---|---|
| Brief Title | Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In Taiwan | ||||
| Official Title | The Treatment For Recurrent Female Breast Cancer After Initial Endocrine Therapy Among Taiwanese Population | ||||
| Brief Summary | Breast cancer is the most common cancer in Taiwanese women. Most of them were diagnosed in relatively early stages. Only 700 metastatic breast cancer were registered in Official Cancer Registration 2012, while more than11,305 were registered as early breast cancer. With broadly application of aromatase inhibitors, hormonal-receptor-positive breast cancer patients can survive longer and longer. However, there is no prevalence of metastatic breast cancer can be available yet. NHIA database coverage is more than 90% population in Taiwan, thus it can be an appropriate surrogate of prevalence. In this retrospective database analysis, we will explore the real world experience on aromatase inhibitor use for breast cancer in Taiwan. | ||||
| Detailed Description | Not Provided | ||||
| Study Type | Observational | ||||
| Study Design | Observational Model: Cohort Time Perspective: Retrospective | ||||
| Target Follow-Up Duration | Not Provided | ||||
| Biospecimen | Not Provided | ||||
| Sampling Method | Non-Probability Sample | ||||
| Study Population | hormonal receptor positive, human epidermal growth factor receptor 2 negative breast cancer | ||||
| Condition | ER/PR(+), Her2(-) Breast Cancer | ||||
| Intervention | Not Provided | ||||
| Study Groups/Cohorts | Not Provided | ||||
| Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||
| Recruitment Information | |||||
| Recruitment Status | Completed | ||||
| Actual Enrollment | 1 | ||||
| Original Estimated Enrollment | Same as current | ||||
| Actual Study Completion Date | April 30, 2018 | ||||
| Actual Primary Completion Date | February 28, 2017 (Final data collection date for primary outcome measure) | ||||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria: - | ||||
| Sex/Gender |
| ||||
| Ages | Child, Adult, Older Adult | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts | Contact information is only displayed when the study is recruiting subjects | ||||
| Listed Location Countries | Taiwan | ||||
| Removed Location Countries | |||||
| Administrative Information | |||||
| NCT Number | NCT02924584 | ||||
| Other Study ID Numbers | A5481066 | ||||
| Has Data Monitoring Committee | No | ||||
| U.S. FDA-regulated Product | Not Provided | ||||
| IPD Sharing Statement |
| ||||
| Responsible Party | Pfizer | ||||
| Study Sponsor | Pfizer | ||||
| Collaborators | Not Provided | ||||
| Investigators |
| ||||
| PRS Account | Pfizer | ||||
| Verification Date | June 2018 | ||||